AU2002225219A1 - Diagnosis and treatment of multiple sclerosis - Google Patents

Diagnosis and treatment of multiple sclerosis

Info

Publication number
AU2002225219A1
AU2002225219A1 AU2002225219A AU2002225219A AU2002225219A1 AU 2002225219 A1 AU2002225219 A1 AU 2002225219A1 AU 2002225219 A AU2002225219 A AU 2002225219A AU 2002225219 A AU2002225219 A AU 2002225219A AU 2002225219 A1 AU2002225219 A1 AU 2002225219A1
Authority
AU
Australia
Prior art keywords
diagnosis
treatment
multiple sclerosis
sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002225219A
Inventor
Herath Mudiyanselage Athula Chandrasiri Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2002225219A1 publication Critical patent/AU2002225219A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
AU2002225219A 2001-01-26 2002-01-25 Diagnosis and treatment of multiple sclerosis Abandoned AU2002225219A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26440401P 2001-01-26 2001-01-26
US60/264,404 2001-01-26
US33164701P 2001-11-20 2001-11-20
US60/331,647 2001-11-20
PCT/GB2002/000330 WO2002059604A2 (en) 2001-01-26 2002-01-25 Diagnosis and treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
AU2002225219A1 true AU2002225219A1 (en) 2002-08-06

Family

ID=26950517

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002225219A Abandoned AU2002225219A1 (en) 2001-01-26 2002-01-25 Diagnosis and treatment of multiple sclerosis

Country Status (4)

Country Link
EP (1) EP1354199A2 (en)
JP (1) JP2004532386A (en)
AU (1) AU2002225219A1 (en)
WO (1) WO2002059604A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US7015004B2 (en) 2001-11-23 2006-03-21 Syn X Pharma, Inc. Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance
US20030113808A1 (en) * 2001-12-13 2003-06-19 George Jackowski Apolipoprotein biopolymer markers predictive of alzheimers disease
CA2527916A1 (en) * 2003-03-14 2004-09-30 Aaron B. Kantor Biological markers for diagnosing rheumatoid arthritis
JP2007500747A (en) 2003-05-15 2007-01-18 ディーエムアイ バイオサイエンシズ インコーポレイテッド Treatment of T cell mediated diseases
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
PL1755661T3 (en) 2004-05-12 2014-10-31 Brigham & Womens Hospital Inc Gelsolin for use in treating infections
WO2005113831A2 (en) * 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Biomarkers for multiple sclerosis and methods of use thereof
WO2006005583A2 (en) * 2004-07-12 2006-01-19 Geneprot Inc. Secreted polypeptide species involved in multiple sclerosis
WO2006069739A2 (en) * 2004-12-27 2006-07-06 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
WO2006074787A2 (en) * 2004-12-27 2006-07-20 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
US20070017809A1 (en) * 2005-07-21 2007-01-25 Power3 Medical Products, Inc. Assay for ALS and ALS-like disorders
WO2007106577A2 (en) * 2006-03-15 2007-09-20 The Brigham And Women's Hospital, Inc. Gelsolin in the treatment and diagnosis of neurological disease
PT3279663T (en) 2006-03-15 2021-09-24 Brigham & Womens Hospital Inc Use of gelsolin to diagnose and treat inflammatory diseases
WO2009020058A1 (en) * 2007-08-03 2009-02-12 Keio University Drug delivery system toward demyelinating lesion and biochemical marker of demyelinating lesion
AU2013276991C1 (en) * 2007-08-13 2016-08-11 Takeda Pharmaceutical Company Limited IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
EP2522755B1 (en) 2007-08-13 2014-04-02 Baxter International Inc. IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease
ES2634263T3 (en) 2008-01-25 2017-09-27 The General Hospital Corporation Therapeutic diagnostic uses of gelsolin in renal failure
JP5856843B2 (en) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド Pharmaceutical composition using diketopiperazine
WO2010005387A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab New method and biomarkers for the diagnosis of multiple sclerosis
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
EP3279668B1 (en) * 2010-12-16 2019-05-15 National Institute of Advanced Industrial Science and Technology Method for enrichment and separation of spinal fluid glycoprotein, method for searching for marker for central nervous system diseases which utilizes the aforementioned method, and marker for central nervous system diseases
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
SG10201608087WA (en) 2011-10-10 2016-11-29 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
MX355446B (en) 2011-10-28 2018-04-18 Ampio Pharmaceuticals Inc Treatment of rhinitis.
ITMI20120865A1 (en) * 2012-05-18 2013-11-19 Antonio Bertolotto BIOMARCERS FOR PATHOLOGIES OF THE CENTRAL NERVOUS SYSTEM
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
KR20170045274A (en) 2014-08-18 2017-04-26 앰피오 파마슈티컬스 인코퍼레이티드 Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
RU2694614C1 (en) * 2019-01-22 2019-07-17 Общество с ограниченной ответственностью "ВЕСТТРЭЙД ЛТД" (ООО "ВЕСТТРЭЙД ЛТД") Method of pathological process activity determining in patients with multiple sclerosis
WO2020172262A1 (en) * 2019-02-19 2020-08-27 James Janine Chromium composition and methods thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295668A (en) * 1998-02-13 2001-05-16 牛津糖科学(英国)有限公司 Methods and compositions for diagnosis of hepatoma

Also Published As

Publication number Publication date
WO2002059604A3 (en) 2003-07-03
WO2002059604A8 (en) 2002-11-21
WO2002059604A2 (en) 2002-08-01
JP2004532386A (en) 2004-10-21
EP1354199A2 (en) 2003-10-22

Similar Documents

Publication Publication Date Title
AU2002225219A1 (en) Diagnosis and treatment of multiple sclerosis
AU2002323258A1 (en) Diagnosis and treatment of vascular disease
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2002247004A1 (en) Methods of diagnosis and treatment of osteoporosis
AU2002367535A1 (en) Diagnosis and treatment of vascular disease
AU2002314466A1 (en) Withasol and methods of use
AU2002259130A1 (en) Agents for treatment of hcv and methods of use
AU2002335085A1 (en) Angiopoietins and methods of use thereof
AU2003268295A1 (en) "diagnosis and treatment of infertility"
AU2002258728A1 (en) Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002326813A1 (en) Diagnosis and treatment of vascular disease
AU2002305151A1 (en) Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
AU3760400A (en) Methods and reagents for the diagnosis and treatment of multiple sclerosis
AU2002341880A1 (en) Diagnosis and treatment of vascular disease
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
AU2002330724A1 (en) Diagnosis, prevention and treatment of cancer
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
EP1409734A4 (en) Diagnosis and treatment of cancer
GB2381272B (en) Diagnosis and treatment of atherosclerosis
AU2002210286A1 (en) Medicine intended for treatment of multiple sclerosis
AU2002249891A1 (en) Compounds and methods for the diagnosis and treatment of babesia infection
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002319591A1 (en) Diagnosis and treatment of vascular disease
AU2002330649A1 (en) Diagnosis and therapy of conditions involving alms1

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase